Literature DB >> 15290861

Aerosol dispersion of respirable particles in narrow size distributions using drug-alone and lactose-blend formulations.

Margaret D Louey1, Michiel Van Oort, Anthony J Hickey.   

Abstract

PURPOSE: To examine the effect of formulation type on the aerosolization of respirable particles in narrow size distributions.
METHODS: Aerosol dispersion of two formulation types (drug alone and 2% w/w drug-lactose blends) containing micronized or spray-dried fluticasone propionate (FP) particles (d50% = 1.3 to 9.6 microm, GSD = 1.8 to 2.2) were examined using cascade impaction at 60 l/min with low and high resistance inhaler devices: Rotahaler and Inhalator, respectively.
RESULTS: The aerosol dispersion of FP particles was significantly affected by the particle size, particle type, inhaler device, and formulation type. Interactions were observed between all factors. Generally, greater powder entrainment was obtained with smaller d50%. Higher emitted doses were obtained from drug-alone formulations of spray-dried FP particles and lactose blends of micronized FP particles. Greater aerosol dispersion of spray-dried FP particles was obtained using lactose-blend formulations with d50% around 4 microm. Greater aerosol dispersion of micronized FP particles was obtained using formulations of drug alone. Larger d50% produced larger mass median aerodynamic diameters.
CONCLUSIONS: Small changes in the particle size within the 1-10-microm range exerted a major influence on aerosol dispersion of jet-milled and spray-dried FP particles using drug-alone and lactose-blend formulations.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15290861     DOI: 10.1023/b:pham.0000032991.74736.3e

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  6 in total

1.  Aerosol dispersion of respirable particles in narrow size distributions produced by jet-milling and spray-drying techniques.

Authors:  Margaret D Louey; Michiel Van Oort; Anthony J Hickey
Journal:  Pharm Res       Date:  2004-07       Impact factor: 4.200

2.  Protein deposition from dry powder inhalers: fine particle multiplets as performance modifiers.

Authors:  P Lucas; K Anderson; J N Staniforth
Journal:  Pharm Res       Date:  1998-04       Impact factor: 4.200

3.  Influence of particle size, air flow, and inhaler device on the dispersion of mannitol powders as aerosols.

Authors:  N Y Chew; H K Chan
Journal:  Pharm Res       Date:  1999-07       Impact factor: 4.200

4.  The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers--implications for in vitro testing.

Authors:  A R Clark; A M Hollingworth
Journal:  J Aerosol Med       Date:  1993

5.  Prediction of drug residence times in regions of the human respiratory tract following aerosol inhalation.

Authors:  P R Byron
Journal:  J Pharm Sci       Date:  1986-05       Impact factor: 3.534

6.  Effect of particle size, air flow and inhaler device on the aerosolisation of disodium cromoglycate powders.

Authors:  N Y Chew; D F Bagster; H K Chan
Journal:  Int J Pharm       Date:  2000-09-25       Impact factor: 5.875

  6 in total
  6 in total

1.  Effect of particle shape on dry particle inhalation: study of flowability, aerosolization, and deposition properties.

Authors:  Meer Saiful Hassan; Raymond Wai Man Lau
Journal:  AAPS PharmSciTech       Date:  2009-10-29       Impact factor: 3.246

2.  Nanoparticle agglomerates of fluticasone propionate in combination with albuterol sulfate as dry powder aerosols.

Authors:  Nashwa El-Gendy; Warangkana Pornputtapitak; Cory Berkland
Journal:  Eur J Pharm Sci       Date:  2011-09-21       Impact factor: 4.384

3.  Investigations into the formulation of metered dose inhalers of salmeterol xinafoate and fluticasone propionate microcrystals.

Authors:  Darragh Murnane; Gary P Martin; Christopher Marriott
Journal:  Pharm Res       Date:  2008-05-29       Impact factor: 4.200

4.  Nifedipine nanoparticle agglomeration as a dry powder aerosol formulation strategy.

Authors:  Carl Plumley; Eric M Gorman; Nashwa El-Gendy; Connor R Bybee; Eric J Munson; Cory Berkland
Journal:  Int J Pharm       Date:  2008-10-25       Impact factor: 5.875

5.  Nanoformulated Remdesivir with Extremely Low Content of Poly(2-oxazoline)-Based Stabilizer for Aerosol Treatment of COVID-19.

Authors:  Jacob D Ramsey; Ian E Stewart; Emily A Madden; Chaemin Lim; Duhyeong Hwang; Mark T Heise; Anthony J Hickey; Alexander V Kabanov
Journal:  Macromol Biosci       Date:  2022-05-26       Impact factor: 5.859

6.  Evidence for the existence of powder sub-populations in micronized materials: aerodynamic size-fractions of aerosolized powders possess distinct physicochemical properties.

Authors:  Sara Jaffari; Ben Forbes; Elizabeth Collins; Jiyi Khoo; Gary P Martin; Darragh Murnane
Journal:  Pharm Res       Date:  2014-12       Impact factor: 4.200

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.